Takeda Pharmaceutical Company Limited (TAK) P/E Ratio History
ExpensiveTrading at 40.5x vs 5Y avg 0.3x · 100th percentile · Material premium to history · Data 2009–2025
Loading P/E history...
P/E Ratio Analysis
As of July 7, 2026, Takeda Pharmaceutical Company Limited (TAK) trades at a price-to-earnings ratio of 40.5x, with a stock price of $15.95 and trailing twelve-month earnings per share of $61.82.
The current P/E is 13711% above its 5-year average of 0.3x. Over the past five years, TAK's P/E has ranged from a low of 0.1x to a high of 1.4x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.5x, TAK trades at a 72% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 199.4x.
Relative to the broader market, TAK commands a significant premium over the S&P 500 median P/E of 25.6x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TAK DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TAK Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
TAK P/E vs Peers
Therapy-focused branded biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $219B | 14.0 | 0.68 | +2% | |
| $295B | 29.1 | 1.33 | +191% | |
| $102B | 11.7 | - | +46% | |
| $297B | 21.6 | 1.41 | +22% | |
| $107B | 7.2Lowest | 0.50Best | +348%Best | |
| $450B | 107.5 | - | -1% | |
| $116B | 16.4 | - | +178% | |
| $624B | 23.5 | 1.58 | +91% | |
| $313B | 17.4 | 0.82 | +8% | |
| $135B | 17.4 | - | -4% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
TAK Historical P/E Data (2009–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | - | $18.52 | $60.38 | 0.3x | -97% |
| FY2025 Q3 | Dec 31 2025 | $15.59 | $35.68 | 0.4x | -96% |
| FY2025 Q2 | - | $14.64 | $10.27 | 1.4x | -87% |
| FY2025 Q1 | Jun 30 2025 | $15.46 | $42.60 | 0.4x | -97% |
| FY2024 Q4 | Mar 31 2025 | $14.87 | $33.45 | 0.4x | -96% |
| FY2024 Q3 | - | $13.24 | $65.11 | 0.2x | -98% |
| FY2024 Q2 | Sep 30 2024 | $14.22 | $90.95 | 0.2x | -99% |
| FY2024 Q1 | Jun 30 2024 | $12.94 | $47.02 | 0.3x | -98% |
| FY2023 Q4 | Mar 31 2024 | $13.89 | $45.61 | 0.3x | -97% |
| FY2023 Q3 | Dec 31 2023 | $14.27 | $56.22 | 0.3x | -98% |
| FY2023 Q2 | Sep 30 2023 | $15.47 | $60.80 | 0.3x | -98% |
| FY2023 Q1 | Jun 30 2023 | $15.71 | $95.88 | 0.2x | -99% |
| FY2022 Q4 | Mar 31 2023 | $16.48 | $101.10 | 0.2x | -99% |
| FY2022 Q3 | Dec 31 2022 | $15.60 | $87.85 | 0.2x | -98% |
| FY2022 Q2 | Sep 30 2022 | $12.97 | $68.26 | 0.2x | -98% |
| FY2022 Q1 | - | $14.04 | $63.06 | 0.2x | -98% |
| FY2021 Q4 | - | $14.32 | $73.57 | 0.2x | -98% |
| FY2021 Q3 | Dec 31 2021 | $13.63 | $139.72 | 0.1x | -99% |
| FY2021 Q2 | - | $16.38 | $150.69 | 0.1x | -99% |
| FY2021 Q1 | Jun 30 2021 | $16.83 | $137.44 | 0.1x | -99% |
| FY2020 Q4 | Mar 31 2021 | $18.26 | $119.50 | 0.2x | -99% |
| FY2020 Q3 | - | $18.20 | $57.51 | 0.3x | -97% |
| FY2020 Q2 | Sep 30 2020 | $17.84 | $17.86 | 1.0x | -91% |
| FY2020 Q1 | - | $17.93 | $38.25 | 0.5x | -96% |
| FY2019 Q4 | - | $15.18 | $5.29 | 2.9x | -75% |
| FY2019 Q2 | Sep 30 2019 | $17.20 | $21.39 | 0.8x | -93% |
| FY2019 Q1 | Jun 30 2019 | $17.70 | $30.45 | 0.6x | -95% |
| FY2018 Q4 | Mar 31 2019 | $20.37 | $86.81 | 0.2x | -98% |
| FY2018 Q3 | Dec 31 2018 | $16.82 | $87.22 | 0.2x | -98% |
| FY2018 Q2 | Sep 30 2018 | $21.37 | $106.57 | 0.2x | -98% |
| FY2018 Q1 | Jun 30 2018 | $20.90 | $93.67 | 0.2x | -98% |
| FY2017 Q4 | Mar 31 2018 | $24.41 | $136.12 | 0.2x | -98% |
| FY2017 Q3 | Dec 31 2017 | $28.45 | $137.17 | 0.2x | -98% |
| FY2017 Q2 | Sep 30 2017 | $27.69 | $120.24 | 0.2x | -98% |
| FY2017 Q1 | Jun 30 2017 | $25.42 | $118.21 | 0.2x | -98% |
| FY2016 Q4 | Mar 31 2017 | $23.64 | $89.39 | 0.3x | -98% |
| FY2016 Q3 | Dec 31 2016 | $20.78 | $94.89 | 0.2x | -98% |
| FY2016 Q2 | Sep 30 2016 | $23.96 | $106.03 | 0.2x | -98% |
| FY2016 Q1 | - | $21.54 | $109.08 | 0.2x | -98% |
| FY2015 Q4 | - | $22.82 | $61.26 | 0.4x | -97% |
| FY2015 Q3 | - | $25.03 | $0.04 | 625.8x | +5430% |
| FY2014 Q3 | Dec 31 2014 | $20.74 | $49.22 | 0.4x | -96% |
| FY2014 Q2 | - | $21.74 | $72.10 | 0.3x | -97% |
| FY2014 Q1 | Jun 30 2014 | $23.25 | $81.39 | 0.3x | -97% |
| FY2013 Q4 | Mar 31 2014 | $23.70 | $82.95 | 0.3x | -97% |
| FY2013 Q3 | - | $23.02 | $81.89 | 0.3x | -98% |
| FY2013 Q2 | Sep 30 2013 | $23.72 | $59.50 | 0.4x | -96% |
| FY2013 Q1 | Jun 30 2013 | $22.58 | $52.82 | 0.4x | -96% |
| FY2012 Q4 | Mar 31 2013 | $27.25 | $50.59 | 0.5x | -95% |
| FY2012 Q3 | Dec 31 2012 | $22.20 | $98.18 | 0.2x | -98% |
| FY2012 Q2 | Sep 30 2012 | $23.09 | $136.81 | 0.2x | -99% |
| FY2010 Q4 | - | $23.36 | $157.00 | 0.1x | -99% |
| FY2010 Q3 | Dec 31 2010 | $24.35 | $160.94 | 0.2x | -99% |
| FY2010 Q2 | - | $22.94 | $159.82 | 0.1x | -99% |
| FY2010 Q1 | Jun 30 2010 | $21.28 | $157.88 | 0.1x | -99% |
| FY2009 Q4 | Mar 31 2010 | $21.90 | $158.97 | 0.1x | -99% |
| FY2009 Q3 | - | $20.55 | $188.94 | 0.1x | -99% |
Average P/E for displayed period: 11.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
17+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TAK — Frequently Asked Questions
Quick answers to the most common questions about buying TAK stock.
What is TAK's P/E ratio?
Takeda Pharmaceutical Company Limited (TAK) trailing twelve-month P/E ratio is 40.5x, based on TTM diluted EPS of $61.82. The 5-year average P/E is 0.3x and the historical range spans 0.1x to 1.4x.
Is TAK stock overvalued or undervalued?
TAK trades at 40.5x P/E, above its 5-year average of 0.3x. The 100th percentile ranking within the 0.1x–1.4x historical range indicates a premium to historical valuation.
Is TAK stock expensive?
Yes, TAK is expensive relative to its own history. The current P/E of 40.5x is above the 5-year average of 0.3x and also above the Healthcare sector median of 23.5x. The stock sits at the 100th percentile of its 5-year valuation range.
What is TAK's historical P/E range?
Over the past 5 years, TAK's P/E ratio has ranged from 0.1x to 1.4x, with a median of 0.2x and an average of 0.3x. The current P/E of 40.5x places the stock at the 100th percentile of this range. Full historical data spans 2009–2025.
How does TAK's P/E compare to the S&P 500?
TAK trades at 40.5x P/E versus the S&P 500 median of 25.6x. The 58% premium to the market typically reflects higher expected earnings growth or quality.
How does TAK's valuation compare to Healthcare peers?
Takeda Pharmaceutical Company Limited P/E of 40.5x compares to the Healthcare sector median of 23.5x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is TAK's PEG ratio?
TAK PEG ratio is N/A, based on a P/E of 40.5x and EPS growth of 90.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is TAK's earnings yield?
TAK earnings yield is 2.47%, the inverse of its 40.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.